NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $11.69 -0.29 (-2.42%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroPace Stock (NASDAQ:NPCE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeuroPace alerts:Sign Up Key Stats Today's Range$11.26▼$11.8650-Day Range$10.04▼$13.8452-Week Range$5.45▼$15.11Volume108,610 shsAverage Volume130,467 shsMarket Capitalization$382.88 millionP/E RatioN/ADividend YieldN/APrice Target$15.20Consensus RatingModerate Buy Company OverviewNeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More… NeuroPace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreNPCE MarketRank™: NeuroPace scored higher than 77% of companies evaluated by MarketBeat, and ranked 372nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 1 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -11.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -11.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 14.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently decreased by 22.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently decreased by 22.71%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment1.59 News SentimentNeuroPace has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NeuroPace this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,620,685.00 in company stock.Percentage Held by Insiders22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Stock News HeadlinesNeuroPace Stock Short Interest Report | NASDAQ:NPCE | BenzingaApril 20, 2025 | benzinga.comNeuroPace, Inc.: NeuroPace Provides Update on Tariff StatusApril 17, 2025 | finanznachrichten.deHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 1, 2025 | Brownstone Research (Ad)NeuroPace expects minimal impact from tariffsApril 15, 2025 | markets.businessinsider.comNeuroPace Provides Update on Tariff StatusApril 14, 2025 | globenewswire.comNeuroPace, Inc.: NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | finanznachrichten.deNeuroPace announces data from long-term post-approval study of RNS SystemApril 8, 2025 | markets.businessinsider.comNeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | globenewswire.comSee More Headlines NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $11.19 on January 1st, 2025. Since then, NPCE shares have increased by 4.5% and is now trading at $11.69. View the best growth stocks for 2025 here. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) posted its quarterly earnings results on Tuesday, March, 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07. The company earned $21.47 million during the quarter, compared to analyst estimates of $21.14 million. NeuroPace had a negative trailing twelve-month return on equity of 205.41% and a negative net margin of 36.74%. Read the conference call transcript. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's top institutional shareholders include Palumbo Wealth Management LLC (0.14%), Bank of New York Mellon Corp (0.09%), Rhumbline Advisers (0.05%) and Calamos Advisors LLC (0.03%). Insiders that own company stock include Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell, Irina Ridley and Ltd Kck. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroPace own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings3/04/2025Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NPCE CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$15.20 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+30.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-36.74% Pretax Margin-36.74% Return on Equity-205.41% Return on Assets-28.29% Debt Debt-to-Equity Ratio6.03 Current Ratio5.59 Quick Ratio4.77 Sales & Book Value Annual Sales$79.91 million Price / Sales4.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book14.80Miscellaneous Outstanding Shares32,753,000Free Float23,222,000Market Cap$382.88 million OptionableOptionable Beta2.03 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:NPCE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.